Epidemiological and economic aspects of chelating therapy in the therapeutic center of thalassemia in Morocco;Aspects épidémiologiques et économiques des traitements chélateurs au centre thérapeutique de la thalassémie au Maroc

Revue Medicale de Bruxelles

Volumn 31, Issue 2, 2010, Pages 79-87

  Agouzal, M ^a   Quyou, A ^a   Benchekroune, K ^b   Khattab, M ^c  

^a IBN TOFAIL UNIVERSITY   (Morocco)

^b Département Marketing   (Morocco)

^c Hopital d'Enfants   (Morocco)

Author keywords

Adverse events; Behavior; Deferiprone; Deferoxamine; Prospective study; Socio economic level

Indexed keywords

CHELATING AGENT; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CHILD; ECONOMIC ASPECT; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH ECONOMICS; HEALTH SURVEY; HUMAN; INFANT; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MOROCCO; MORTALITY; NEWBORN; SAMPLE SIZE;

EID: 77954521503     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Girot R : La drépanocytose : de l'enfance à l'âge adulte. Archives de la pédiatrie 2007 ; 14 : 605-6
2. Fédération française des associations de malades de l'hémochromatose. [02/06/2009]. Place des chélateurs du fer dans le traitement de l'hémochromatose [en ligne] 2008. http://www.ffamh. hemochromatose.org/spip/spip.php?article290
3. Emmanuele A, Giovanni B, Clara C, Maria D, Mario, Renzo G : Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008 ; 93 : 741-52
4. Smiers FJ, Krishnamurti L, Lucarelli G : Hematopoietic Stem Cell Transplantation for Hemoglobinopathies : current practice and emerging trends. Pediatr Clin North Am, in press
5. Hoffbrand V, Cohen A, Hershko C : Role of deferiprone in chélation therapy for transfusional iron overload. Blood 2003 ; 102 : 7-24
6. Girot R : Traitement de la surcharge en fer dans les maladies hématologiques (hémochromatoses héréditaires exclues). Hématologie 2006 ; 42 : 247-51
7. Aurelio M, Angela V, Marcello C et al. : Improving survival with deferiprone treatment in patients with thalassemia major : A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis 2009 ; 42 : 247-51
8. Maggio A, Vitrano A, Capra M et al. : Deferiprone treatment Improving survival with in patients with thalassemia major : a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies, 2009
9. Borgna-Pignati C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC : Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004 ; 89 : 1187-93
10. Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ : Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin 2008 ; 32 : 41-7
11. Cappellini M : Long term efficacy and safety of deferasirox. Blood Reviews 2008 ; 22 (Suppl 2) : S35-S41
12. Agouzal M, Quyou A, El Khattab M : Prévalence de la bêta- thalassémie au Nord-ouest du Maroc. Revue marocaine des maladies de l'enfant, sous presse
13. El Beshlawy A, Manz M, Naja M, Eltagui M, Tarabishi C, Youssry I : Iron chelation in thalassemia : combined or monotherapy ? The Egyptian experience. Ann Hematol 2008 ; 87 : 545-50
14. Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD : Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients : US healthcare perspective. PharmacoEconomics 2007 ; 25 : 329-42
15. Rose C, Thuret I, Ernst O : Hémochromatose post- transfusionnelle. Paris, Elsevier Hématologie, 2008
16. Girot R : Utilisation des chélateurs du fer dans le traitement préventif et curatif de l'hémochromatose secondaire. Médecine thérapeutique 1997 ; 3 : 821
17. Modell B, Darlison M : Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization 2008 ; 86 : 480-7